Alzheimer’s disease(AD)threatens the foundations of humanity and our society.AD is a neurological disorder primarily affecting the elderly through memory disorders,cognitive decline,and loss of autonomy.The dramatic ...Alzheimer’s disease(AD)threatens the foundations of humanity and our society.AD is a neurological disorder primarily affecting the elderly through memory disorders,cognitive decline,and loss of autonomy.The dramatic consequences of this late-onset disease were illustrated sensitively in Michael Haneke’s masterpiece,Amour.Researchers and governments have invested colossal efforts to develop a treatment for this terrible disease.Currently and in the past decade the amyloid cascade has dominated the therapeutic research on AD,but the absence of benefit for patients treated with drugs that reduce brain amyloid deposit questions the role ofβ-amyloid as a causative agent(Herrup,2021).The recent approval of aducanumab by the United States Food and Drug Administration,a drug that targetsβ-amyloid,is at the center of a scandal among clinicians and researchers,as it does not provide therapeutic benefits to patients and is listed among the breakdowns of the year 2021 by Science magazine(Voosen et al.,2021).The lack of progress in curing AD and recent therapeutic failures calls for further exploratory research.展开更多
基金funded by the Agence Nationale pour la Recherche,Fondation Vaincre Alzheimer and Sorbonne Université。
文摘Alzheimer’s disease(AD)threatens the foundations of humanity and our society.AD is a neurological disorder primarily affecting the elderly through memory disorders,cognitive decline,and loss of autonomy.The dramatic consequences of this late-onset disease were illustrated sensitively in Michael Haneke’s masterpiece,Amour.Researchers and governments have invested colossal efforts to develop a treatment for this terrible disease.Currently and in the past decade the amyloid cascade has dominated the therapeutic research on AD,but the absence of benefit for patients treated with drugs that reduce brain amyloid deposit questions the role ofβ-amyloid as a causative agent(Herrup,2021).The recent approval of aducanumab by the United States Food and Drug Administration,a drug that targetsβ-amyloid,is at the center of a scandal among clinicians and researchers,as it does not provide therapeutic benefits to patients and is listed among the breakdowns of the year 2021 by Science magazine(Voosen et al.,2021).The lack of progress in curing AD and recent therapeutic failures calls for further exploratory research.
